secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2024-11-21T23:59:59+00:00
Accession:  0001493152-24-047149
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce stockholders approve reverse stock split authorization and director elections at annual meeting
--------------------------------------------------------------------------------

- Approved issuance of shares/warrants to investors: 3,102,053 for, 210,141 against (3,995,063 broker non-votes).
- Authorized reverse stock split with ratio range 1-for-10 to 1-for-40; board sets exact ratio: 4,561,369 for, 1,989,571 against.
- Elected Class III directors Dr. Lynn Kirkpatrick, Dr. Adam Levin, and Mr. Steve Martin (each >2M votes for).
- Ratified Moss Adams LLP as auditor for FY 2024: 5,978,860 for, 259,207 against, 1,250,026 abstentions.
- Fifth proposal to adjourn meeting if needed was not voted on.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315224047149/0001493152-24-047149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315224047149/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-047149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer